Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
A8K2U0
UPID:
A2ML1_HUMAN
Alternative names:
C3 and PZP-like alpha-2-macroglobulin domain-containing protein 9
Alternative UPACC:
A8K2U0; B5MDD1; B7Z7V4; D3DUV3; F5H2Z2; Q2M224; Q6ZW52; Q6ZW53; Q8N1M4; Q96LQ8
Background:
Alpha-2-macroglobulin-like protein 1, also known as C3 and PZP-like alpha-2-macroglobulin domain-containing protein 9, plays a crucial role in the body's defense mechanism. It inhibits a wide range of proteinases through a unique 'trapping' mechanism, involving a bait region that undergoes a conformational change upon cleavage, entrapping the proteinase. This protein is particularly effective against chymotrypsin, papain, thermolysin, subtilisin A, and to a lesser extent, elastase.
Therapeutic significance:
Given its role in inhibiting extracellular proteases, Alpha-2-macroglobulin-like protein 1 is implicated in otitis media, a condition characterized by ear inflammation and hearing disturbances. Understanding the role of Alpha-2-macroglobulin-like protein 1 could open doors to potential therapeutic strategies for otitis media and other protease-related conditions.